 |
Molika Ashford is a GenomeWeb contributing editor and covers personalized medicine and molecular diagnostics. E-mail Molika Ashford. |
Prospective Study Suggests Site-Specific Treatment after BioTheranostics' CUP Testing Improves Survival
October 17, 2012
Prospective Study Suggests Site-Specific Treatment after BioTheranostics' CUP Testing Improves Survival
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Prospective Validation Confirms Sensitivity of Veracyte's Gene Expression Test for Thyroid Nodule Risk
June 27, 2012 / Pharmacogenomics Reporter - Pathwork's Economics Study Finds TOO Test 'Strongly' Cost-Effective in Extending Survival
January 18, 2012 / Pharmacogenomics Reporter - Prostate Cancer Risk Markers Show Promise for Test to ID Elevated Risk in Men with Benign Hyperplasia
April 3, 2013 / Pharmacogenomics Reporter - Rosetta Gets Medicare Coverage for mets2 Assay; Stock Soars
May 16, 2012 / GenomeWeb Daily News - Sequencing Study Suggests Potential New Treatments for ALL Subset with Poor Response
January 25, 2012 / Pharmacogenomics Reporter